Long-Term Outcome Of Acalabrutinib In MCL

Long-Term Outcome Of Acalabrutinib In MCL

User Photo
obr

1 year
45 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center Discusses Long-Term Outcome Of Acalabrutinib In MCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Up Next Autoplay